Nirsevimab may curb RSV severity

Real-world estimates showed protection across emergency, inpatient, and intensive care settings during Canada’s first universal immunization season.

1

Nirsevimab may effectively reduce respiratory syncytial virus disease severity requiring hospital care among infants in Canada.
2

The study included 1,942 symptomatic infants under 12 months who underwent RSV testing during the 2024-2025 season.
3

Adjusted effectiveness of nirsevimab against laboratory-confirmed RSV was 78%, with 97% effectiveness against ICU admissions.
4

Effectiveness varied by subgroup, with 90% among premature infants and 86% among those with high-risk comorbidities.
5

Limitations included variability in testing practices and potential misclassification of nirsevimab receipt among caregivers.

1